Q32 Bio Inc. reported financial results for the fourth quarter and full year ended December 31, 2024, on March 11, 2025. For the fourth quarter, the company reported a net loss of $14.189 million, compared to a net loss of $27.067 million in Q4 2023. The net loss per share for the quarter was $1.16.
For the full year 2024, Q32 Bio reported a net loss of $47.733 million, an improvement from a net loss of $53.743 million in 2023. Research and development expenses for the fourth quarter were $10.545 million, while general and administrative expenses were $3.981 million. The company did not report any collaboration arrangement revenue for the quarter or the full year.
As of December 31, 2024, Q32 Bio held $78.0 million in cash and cash equivalents. Management expects this capital to provide a financial runway into the second half of 2026. The company also highlighted the recent late-breaking oral presentation of bempikibart SIGNAL-AA Phase 2a Part A data at the 2025 American Academy of Dermatology Annual Meeting, which demonstrated encouraging clinical activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.